This is a StreetInsider.com Premium Only Page

Verastem Oncology (VSTM) – StreetInsider.com Reports

Apr 18, 2024 04:05 PM Verastem Oncology (VSTM) Appoints John Hayslip to Chief Medical Officer

Mar 14, 2024 05:43 PM Verastem Oncology (VSTM) Misses Q4 EPS by 102c

Feb 9, 2024 08:28 AM Mizuho Securities Assumes Verastem (VSTM) at Buy

Jan 29, 2024 07:04 AM Verastem Oncology (VSTM) Outlines Key 2024 Strategic Priorities and Upcoming Catalysts

Jan 18, 2024 04:00 PM Verastem Oncology (VSTM) Granted FDA Fast Track Designation for Combination of Avutometinib and Sotorasib

Dec 18, 2023 07:11 AM Verastem Oncology (VSTM) Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

Dec 13, 2023 07:16 AM Verastem Oncology (VSTM) Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Nov 21, 2023 05:37 AM BTIG Assumes Verastem (VSTM) at Buy

Nov 15, 2023 07:17 AM Verastem (VSTM) PT Lowered to $34 at Truist Securities

Nov 9, 2023 07:52 AM Verastem Oncology (VSTM) Tops Q3 EPS by 8c

Nov 8, 2023 05:03 PM Verastem Oncology (VSTM) Files $300M Mixed Shelf

Nov 6, 2023 07:01 AM Verastem Oncology (VSTM) Reports Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

Oct 26, 2023 04:16 PM Verastem Oncology (VSTM) Strengthens Executive Leadership Team with Key Appointments

Sep 26, 2023 08:02 PM B.Riley Starts Verastem (VSTM) at Buy, "Verastem’s combo regimen is poised for strong market penetration"

Aug 28, 2023 07:02 AM Verastem Oncology (VSTM) Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

Aug 9, 2023 06:21 AM Verastem (VSTM) PT Lowered to $32 at RBC Capital

Aug 8, 2023 05:32 PM Verastem (VSTM) Misses Q2 EPS by 26c

Jul 11, 2023 07:14 AM Verastem (VSTM) PT Lowered to $39 at Truist Securities

Jul 11, 2023 07:00 AM Verastem Oncology (VSTM) Appoints Dan Peterson as CEO

Jul 5, 2023 04:06 PM Verastem Oncology (VSTM) Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Jul 3, 2023 06:13 AM Verastem (VSTM) PT Lowered to $34 at RBC Capital

Jun 16, 2023 05:54 AM Verastem Oncology (VSTM) Prices 7.18M Share and Warrant Offering at $9.75/sh

Jun 15, 2023 04:00 PM Verastem Oncology (VSTM) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 15, 2023 04:57 AM Mizuho Securities Upgrades Verastem (VSTM) to Buy, 'Positive RAMP 201 Showing at ASCO'

May 31, 2023 09:11 AM Verastem Oncology (VSTM) Announces 1-for-12 Reverse Stock Split

May 25, 2023 05:07 PM Verastem Oncology (VSTM) Reports Updated Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib

May 16, 2023 07:04 AM Verastem Oncology (VSTM) Appoints Karin Tollefson to its Board

May 9, 2023 05:43 PM Verastem (VSTM) Misses Q1 EPS by 1c

Mar 29, 2023 04:03 PM Mizuho Securities Starts Verastem (VSTM) at Neutral

Mar 14, 2023 04:50 PM Verastem (VSTM) Tops Q4 EPS by 2c

Feb 2, 2023 07:02 AM Verastem Oncology (VSTM) Outlines Key 2023 Strategic Priorities and Upcoming Catalysts

Jan 25, 2023 05:41 AM Verastem Oncology (VSTM) Announces Up to $60M Private Placement of Preferred Stock

Jan 25, 2023 05:40 AM Verastem Oncology (VSTM) Reports Positive Data and Regulatory Update from Interim Analysis of Phase 2 Trial of RAMP-201

Dec 15, 2022 04:31 PM Verastem Oncology (VSTM) Appoints Rob Gagnon to its Board

Nov 21, 2022 07:37 AM Verastem (VSTM) PT Lowered to $5 at Truist Securities

Nov 7, 2022 06:59 AM Verastem (VSTM) PT Lowered to $3 at H.C. Wainwright

Nov 4, 2022 06:33 AM Verastem (VSTM) PT Lowered to $3 at RBC Capital

Oct 5, 2022 06:19 AM Verastem (VSTM) PT Lowered to $5 at BTIG

Oct 4, 2022 07:00 AM Verastem Oncology (VSTM) Announces RAMP VS-6766 Clinical Trials and Corporate Updates

Sep 26, 2022 09:53 AM Truist Securities Reiterates Buy Rating on Verastem (VSTM), FV is $5

Jun 6, 2022 07:04 AM Verastem Oncology (VSTM) Issues Update on RAMP 201 Study of VS-6766 ± Defactinib

May 18, 2022 08:46 AM Verastem Oncology (VSTM) Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Canc

Apr 29, 2022 07:21 AM Cantor Fitzgerald Starts Verastem (VSTM) at Overweight

Apr 14, 2022 04:01 AM UPDATE: RBC Capital Starts Verastem (VSTM) at Outperform

Mar 9, 2022 06:16 AM UPDATE: Truist Securities Starts Verastem (VSTM) at Buy

Jan 11, 2022 07:08 AM Verastem Oncology (VSTM) Outlines Key 2022 Strategic Priorities and Upcoming Catalysts

Nov 22, 2021 07:33 AM Mirati Therapeutics (MRTX), Verastem Oncology (VSTM) Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant NSCLC

Oct 26, 2021 07:08 AM Verastem Oncology (VSTM) Appoints Michelle Robertson to its Board

Sep 22, 2021 07:05 AM Verastem Oncology (VSTM) Appoints Louis J. Denis, M.D., as Chief Medical Officer

Sep 20, 2021 09:30 AM Pre-Open Stock Movers 09/20: (VSTM) (SYBX) (SDC) Higher; (DOCN) (LI) (XPEV) Lower (more...)